Elsaad products
Member Login

New Products
Our Products
Product Name
Chemical Name
Meclizine HCl + Vitamin B6
Therapeutic Category
Miscellaneous drugs
Pharmacologic Category
Antiemetic - Histamine H1; Antagonist - Histamine H1; Antagonist, First Generation - Piperazine Derivative
Pharmaceutical Form
Meclizine HCl + Vitamin B6
Monitoring Parameters
Dosing: Adult
Motion sickness: Oral: 12.5-25 mg 1 hour before travel, repeat dose every 12-24 hours if needed; doses up to 50 mg may be needed
Vertigo: Oral: 25-100 mg/day in divided doses

Dosing: Pediatric

Children >12 years: Refer to adult dosing.

Dosing: Geriatric

Refer to adult dosing.
Prevention and treatment of symptoms of motion sickness; management of vertigo with diseases affecting the vestibular system
Adverse Reactions
Central nervous system: Slight to moderate drowsiness
Respiratory: Thickening of bronchial secretions
1% to 10%:
Central nervous system: Headache, fatigue, nervousness, dizziness
Gastrointestinal: Appetite increase, weight gain, nausea, diarrhea, abdominal pain, dry mouth
Respiratory: Pharyngitis
<1% (Limited to important or life-threatening): Bronchospasm, hepatitis, hypotension, palpitation
Hypersensitivity to meclizine or any component of the formulation
Warnings / Precautions Drug
Concerns related to adverse effects:
• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).
Disease-related concerns:
• Asthma: Use with caution in patients with asthma.
• Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade. Screening is recommended.
• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.
• Pyloric/duodenal obstruction: Use with caution in patients with pyloric or duodenal obstruction.
Special populations:
• Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.
• Pediatrics: Safety and efficacy have not been established in children <12 years of age.
Concurrent drug therapy issues:
• Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.
Other warnings/precautions:
• Lack of response: If vertigo does not respond in 1-2 weeks, it is advised to discontinue use.
Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial. Risk C: Monitor therapy
Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Risk C: Monitor therapy
Amphetamines: May diminish the sedative effect of Antihistamines. Risk C: Monitor therapy
Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics. Exceptions: Levocabastine (Nasal); Paliperidone. Risk C: Monitor therapy
Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects. Risk D: Consider therapy modification
Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Risk C: Monitor therapy
CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Exceptions: Levocabastine (Nasal). Risk C: Monitor therapy
Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use. Risk D: Consider therapy modification
HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract. Risk D: Consider therapy modification
Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Risk C: Monitor therapy
Pregnancy Implications
No data available on crossing the placenta. Probably no effect on the fetus (insufficient data). Available evidence suggests safe use during pregnancy.
Excretion in breast milk unknown/not recommended
Mechanism of Action
Has central anticholinergic action by blocking chemoreceptor trigger zone; decreases excitability of the middle ear labyrinth and blocks conduction in the middle ear vestibular-cerebellar pathways
Pharmacodynamics / Kinetics
Onset of action: ∼1 hour
Duration: 8-24 hours
Metabolism: Hepatic
Half-life elimination: 6 hours
Excretion: Urine (as metabolites); feces (as unchanged drug)
Powered by: TSS-EST.COM